ArticleCancer cell2014
Sox2: masterminding the root of cancer.
Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Transcriptional activation of EPHB1 by SOX2 promotes epithelial-mesenchymal transition and metastasis in esophageal squamous cell carcinoma.Clinical & experimental metastasis · 2026Article
- Disrupting SOX2 self-association and condensate formation to overcome chemotherapeutic drug resistance in lung squamous cell carcinoma.Signal transduction and targeted therapy · 2026Article
- SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape.Nature communications · 2025Article
- SOX2 Expression Does Not Guarantee Cancer Stem Cell-like Characteristics in Lung Adenocarcinoma.Cells · 2024Article
- Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity.Stem cells international · 2024Article
- Control of SOX2 protein stability and tumorigenic activity by E3 ligase CHIP in esophageal cancer cells.Oncogene · 2023Article
- The DMRTA1-SOX2 positive feedback loop promotes progression and chemotherapy resistance of esophageal squamous cell carcinoma.Oncology research · 2023Article
- Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma.Journal for immunotherapy of cancer · 2020Article
- Molecular characterization of AwSox2 from bivalveInnate immunity · 2020Article
- Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2.Scientific reports · 2020Article
- SOX2 in cancer stemness: tumor malignancy and therapeutic potentials.Journal of molecular cell biology · 2020Article
- TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription.Nature communications · 2019Article
- AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation.Oncogene · 2019Article
- SOX2 recruits KLF4 to regulate nasopharyngeal carcinoma proliferation via PI3K/AKT signaling.Oncogenesis · 2018Article
- Identification of hub genes with prognostic values in gastric cancer by bioinformatics analysis.World journal of surgical oncology · 2018Article
- New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.Bioorganic & medicinal chemistry · 2018Article
- Upregulation of SOX2-activated lncRNA ANRIL promotes nasopharyngeal carcinoma cell growth.Scientific reports · 2018Article
- XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics · 2018Article
- Article
- Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin EOncotarget · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcription factor Sox2 is a master regulator that maintains stemness in embryonic stem cells and neural stem cells. Using elegant lineage tracing strategies and genetic reporter mouse models, two studies (one of which is by Vanner and colleagues in this issue of Cancer Cell) now demonstrate that rare Sox2-expressing cells are the founding cancer stem cell population driving tumor initiation and therapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.